Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706763 | 0.89 | MCHR1 (0.72) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6705801 | 0.88 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6706726 | 0.88 | MCHR1 (0.71) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6705951 | 0.88 | MCHR1 (0.66) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6708072 | 0.86 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6704705 | 0.85 | MCHR1 (0.57) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6706057 | 0.85 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6225286 | 0.85 | MCHR1 (0.44) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6705897 | 0.81 | MCHR1 (0.53) | MCHR1CHRM1HTR2ACYP2D6NPC1 | |
| SCHEMBL6704624 | 0.80 | NPC1 (0.61) | MCHR1CHRM1HTR2ACYP2D6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MCHR1 2/4885CHRM1 295/4885HTR2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.